Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial by M. Proietti et al.
Journal of the American Heart Association
J Am Heart Assoc. 2020;9:e014932. DOI: 10.1161/JAHA.119.014932 1
 
ORIGINAL RESEARCH
Comprehensive Management With the 
ABC (Atrial Fibrillation Better Care) Pathway 
in Clinically Complex Patients With Atrial 
Fibrillation: A Post Hoc Ancillary Analysis 
From the AFFIRM Trial
Marco Proietti, MD, PhD; Giulio Francesco Romiti, MD; Brian Olshansky, MD; Deirdre A. Lane, PhD;  
Gregory Y. H. Lip , MD
BACKGROUND: For patients with atrial fibrillation, a comprehensive care approach based on the Atrial fibrillation Better Care 
(ABC) pathway can reduce the occurrence of adverse outcomes. The aim of this paper was to investigate if an approach 
based on the ABC pathway is associated with a reduced risk of adverse events in “clinically complex” atrial fibrillation patients, 
including those with multiple comorbidities, polypharmacy, and prior hospitalizations.
METHODS AND RESULTS: We performed a post hoc analysis of the AFFIRM (Atrial Fibrillation Follow- up Investigation of Rhythm 
Management) trial. The principal outcome was the composite of all- cause hospitalization and all- cause death. An integrated 
care approach (ABC group) was used in 3.8% of the multimorbidity group, 4.0% of the polypharmacy group, and 4.8%, of the 
hospitalized groups. In all “clinically complex” groups, the cumulative risk of the composite outcome was significantly lower in 
patients managed consistent with the ABC pathway versus non- ABC pathway- adherent (all P<0.05). Cox regression analysis 
showed a reduction of composite outcomes in ABC pathway- adherent versus non- ABC pathway- adherent for multimorbid-
ity (hazard ratio [HR], 0.61, 95% CI, 0.44–0.85), polypharmacy (HR, 0.68, 95% CI, 0.47–1.00), and hospitalization (HR, 0.59, 
95% CI, 0.42–0.85) groups. Secondary analyses showed that the higher number of ABC criteria fulfilled the larger associated 
reduction in relative risk, even for secondary outcomes considered.
CONCLUSIONS: Use of an ABC consistent pathway is associated with fewer major adverse events in patients with atrial fibrilla-
tion who have multiple comorbidities, use of polypharmacy, and prior hospitalization.
Key Words: atrial fibrillation ■ integrated care ■ outcomes research
See Editorial by Yao et al.
Patients affected with atrial fibrillation (AF) are at high risk for cardiovascular and noncardiovas-cular death.1–6 This risk is associated with mul-
tiple comorbidities,7,8 polypharmacy6,9,10, and prior 
hospitalization,11,12 all features that characterize the 
“clinically complex” patient.
Evidence has emerged indicating that an integrated 
or holistic management approach in patients with AF 
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can reduce mortality associated with AF.13 These data, 
together with the need to reduce major adverse events 
in AF patients beyond just the risk of ischemic stroke, 
have inspired new thinking regarding a multifaceted 
approach to AF management.14–16 The Atrial fibrilla-
tion Better Care (ABC) pathway has been proposed to 
streamline implementation of an integrated approach 
to managing patients with AF.16
The ABC pathway has 3 main pillars: “A” Avoid 
stroke (with Anticoagulants); “B” Better symptom man-
agement, with patient- centered decisions on rate or 
rhythm control; “C” Cardiovascular and Comorbidity 
risk optimization.16 Thus far, retrospective analyses 
have shown that management resembling the ABC 
pathway has been associated with reduction in AF- 
related clinical outcomes.17–19 In a post hoc analysis 
derived from the AFFIRM (Atrial Fibrillation Follow- up 
Investigation of Rhythm Management) trial, we previ-
ously showed how a clinical approach based on ABC 
pathway was associated with reduction in risk for 
major bleeding, all- cause death, cardiovascular death, 
first hospitalization, first cardiovascular hospitalization, 
and multiple hospitalizations.17
Here, we investigate if an approach based on 
the ABC pathway is associated with reduced risk of 
adverse events in 3 prespecified subgroups of “clin-
ically complex” AF patients at high risk for all- cause 
death and other adverse outcomes, including those 
with multiple comorbidities, those taking multiple drugs 
(polypharmacy), and those hospitalized when AF was 
diagnosed.
METHODS
The authors declare that all supporting data and meth-
ods used to derive the results and the related findings 
are available within the article.
We considered patients enrolled in the AFFIRM 
trial.20,21 The AFFIRM trial was approved by the 
University of Missouri Institutional Review Board (IRB); 
the database was obtained from the National Institutes 
of Health. The IRB for every participating center ap-
proved the study protocol and all patients entered the 
study after providing written informed consent. The 
study was performed according to the European Union 
Note for Guidance on Good Clinical Practice CPMP/
ECH/135/95 and the Declaration of Helsinki.
Implementation of the ABC pathway in the AFFIRM 
trial cohort has been described in detail elsewhere.17 In 
brief, the “A” criterion was fulfilled if the patient had a 
time in therapeutic range ≥70%; the “B” criterion was 
fulfilled if the patient presented with 2 or fewer symp-
toms; the “C” criterion was fulfilled if the patient were 
properly managed for the concomitant cardiovascular 
comorbidities (hypertension, coronary artery disease, 
peripheral artery disease, previous stroke/transient 
ischemic attack, heart failure).17
We defined 3 groups of “clinically complex” patients, 
deemed at high risk for adverse AF- related outcomes: 
(1) multimorbidity group: if the patient had 2 or more 
concomitant conditions,22 among the 11 listed in the 
AFFIRM case report form (myocardial infarction, heart 
failure, hypertension, cardiomyopathy, valvular heart 
disease, congenital heart disease, previous stroke/
transient ischemic attack, peripheral arterial disease, 
diabetes mellitus, hepatic/renal disease, pulmonary 
disease); (2) polypharmacy group: if the patient used 
5 or more drugs, as reported in a previous paper from 
the same cohort6; (3) hospitalization group: if the pa-
tient was hospitalized at the time of the index AF event, 
as was originally included in the AFFIRM study.
Study Outcomes
The primary outcome considered was a composite 
of all- cause hospitalization and all- cause death. We 
separately considered all- cause hospitalization and all- 
cause death as independent outcomes. We also con-
sidered occurrence of cardiovascular events, defined 
as stroke, major bleeding, cardiovascular hospitaliza-
tion, or cardiovascular death, as additional outcomes. 
CLINICAL PERSPECTIVE
What Is New?
• In this post hoc analysis, we demonstrated that 
in clinically complex atrial fibrillation patients (ie, 
those presenting with multimorbidity, polyphar-
macy, and a recent hospitalization), a clinical 
management adherent to the Atrial fibrillation 
Better Care (ABC) pathway, an approach to 
streamline the integrated care in AF, is associated 
with a reduction in major adverse events risk.
What Are the Clinical Implications?
• In high-risk group of atrial fibrillation patients, 
such as those more clinically complex, the ap-
plication of a more integrated, holistic, clinical 
approach that would take account of all the 
aspects related to the general and specific 
management of the disease would entail a sig-
nificant and substantial reduction of all major 
adverse outcomes.
Nonstandard Abbreviations and Acronyms
ABC Atrial fibrillation Better Care
AFFIRM  Atrial Fibrillation Follow-up Investigation 
of Rhythm Management
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Finally, we considered occurrence of any clinical event 
among those described previously as a study outcome. 
All the specific clinical events (ie, not those composite) 
were adjudicated centrally, according to the original 
study protocol.20
Statistical Analysis
All continuous variables were reported as median and 
interquartile range (IQR). Categorical variables were 
expressed as counts and percentages and compared 
using the chi- square test.
Cumulative incidence of adverse events is shown 
using Kaplan–Meier curves and compared across the 
groups with the log- rank test. Cox regression was used 
to assess the association between the use of integrated 
care adherent to the ABC pathway and the occurrence 
of outcomes. Covariates considered for adjustment 
were age, sex, diabetes mellitus, hepatic/renal disease, 
pulmonary disease, first AF episode, and use of as-
pirin and were implemented in the various models as 
reported specifically in the tables and figures.
The main analyses included comparisons between 
the ABC pathway consistent group versus the non- ABC 
pathway group. A secondary analysis examined the re-
lationship between the total number of ABC pathway 
criteria fulfilled and occurrence of the study outcomes. 
Finally, a sensitivity analysis examined the degree of 
overlap between the 3 subgroups and the impact of 
the ABC adherent management. A 2- sided P<0.05 was 
considered statistically significant. All analyses were 
performed using SPSS v. 25.0 (IBM, Armonk, NY).
RESULTS
From the original AFFIRM cohort, a total of 3169 (78.0%) 
patients were available for this analysis.17 Baseline 
characteristics of this cohort are reported in Table 1. 
Median (IQR) age was 70 (65–76) years, 1237 (39.0%) 
were female, median (IQR) CHA2DS2- VASc score was 
3 (2–4) and median (IQR) time in therapeutic range was 
67.9% (51.5–81.0%). Of this cohort, 222 (7.0%) were 
managed consistent with the ABC pathway.17
The multimorbidity group comprised 1723 (54.4%) 
patients, 1222 (38.6%) were included in the polyphar-
macy group, and 1360 (42.9%) in the hospitalization 
group. Baseline characteristics for the 3 groups are 
summarized in Table  1. Median age was similar be-
tween the groups, with a slightly lower prevalence of 
females in the multimorbidity group. CHA2DS2- VASc 
score was numerically higher in the multimorbidity 
group compared with the overall cohort and the other 
subgroups. ABC pathway consistent management 
Table 1. Baseline Characteristics of the Overall Cohort and Clinically Complex Subgroups
Overall Cohort 
N=3169
Multimorbidity 
N=1723
Polypharmacy 
N=1222
Hospitalization 
N=1360
Age y, median (IQR) 70 (65–76) 70 (64–76) 71 (65–76) 70 (65–76)
Female sex, n (%) 1237 (39.0) 656 (38.1) 530 (43.4) 586 (43.1)
Hypertension, n (%) 2243 (70.8) 1445 (83.9) 1009 (82.6) 979 (72.0)
Diabetes mellitus, n (%) 625 (19.7) 576 (33.4) 325 (26.6) 306 (22.5)
Smoking, n (%) 378 (11.9) 256 (14.9) 167 (13.7) 179 (13.2)
Coronary artery disease, n (%) 1164 (36.7) 873 (50.7) 653 (53.4) 567 (41.7)
Myocardial infarction, n (%) 523 (16.5) 489 (28.4) 333 (27.3) 262 (19.3)
Peripheral arterial disease, n (%) 202 (6.4) 190 (11.0) 112 (9.2) 103 (7.6)
Stroke/TIA, n (%) 431 (13.6) 379 (22.0) 195 (16.0) 235 (17.3)
Heart failure, n (%) 684 (21.6) 659 (38.2) 442 (36.2) 393 (28.9)
Valvular heart disease, n (%) 401 (12.7) 354 (20.5) 192 (15.7) 177 (13.0)
Hepatic/renal disease, n (%) 158 (5.0) 149 (8.6) 88 (7.2) 87 (6.4)
Pulmonary disease, n (%) 427 (13.5) 375 (21.8) 199 (16.3) 226 (16.6)
First AF episode, n (%) 1016 (33.1)* 610 (36.5)† 419 (34.3)‡ 556 (43.0)§
Use of aspirin, n (%) 772 (24.4) 468 (27.2) 462 (37.8) 413 (30.4)
CHA2DS2- VASc, median (IQR) 3 (2–4) 4 (3–4) 3 (2–4) 3 (2–4)
TTR %, median (IQR) 67.9 (51.5–81.0) 65.9 (48.1–80.0) 67.1 (49.3–80.8) 63.4 (46.3–79.2)
ABC pathway adherent patients, n (%) 222 (7.0) 66 (3.8) 49 (4.0) 65 (4.8)
Follow- up time y, median (IQR) 3.70 (2.82–4.59) 3.63 (2.73–4.54) 3.59 (2.73–4.49) 3.78 (2.89–4.67)
ABC indicates Atrial fibrillation Better Care; AF, atrial fibrillation; IQR, interquartile range; TIA, transient ischemic attack; and TTR, time in therapeutic range.
*Available for 3067 patients.
†Available for 1673 patients.
‡Available for 1222 patients.
§Available for 1292 patients.
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was found in 66 (3.8%) in the multimorbidity group, 49 
(4.0%) in the polypharmacy group, and in 65 (4.8%) for 
the hospitalization group.
Follow- Up Analysis
In the multimorbidity group, after a median (IQR) 3.63 
(2.73–4.54) years of follow- up, there were 1238 com-
posite outcome events (37.8 per 100  patient- years), 
1185 hospitalization events (36.2 per 100  patient- 
years), 262 all- cause death (4.21 per 100 patient- years), 
855 cardiovascular events (20.3 per 100 patient- years), 
and a total of 1245 “any event” outcomes (38.3 per 
100 patient- years). Event rates for the non- ABC group 
was significantly higher than the ABC group for all out-
comes considered (Figure 1A).
In the polypharmacy group, after a median (IQR) 
3.59 (2.73–4.49) years of follow- up, a similar rate of 
events was evident, except for all- cause death, which 
was numerically lower than in the multimorbidity group. 
There were 865 composite outcome events (37.7 per 
100  patient- years), 833 hospitalizations (36.3 per 
100 patient- years), 165 deaths (3.76 per 100 patient- 
years), 599 cardiovascular events (20.5 per 100 patient- 
years), and a total of 870 “any event” outcomes (38.4 
per 100  patient- years). The overall rate of outcomes 
was higher in non- ABC pathway- adherent group than 
in ABC pathway- adherent group (see Figure 1), except 
for all- cause death (P=0.123) (Figure 1B).
A similar rate of events was reported in the hospi-
talization group, with 967 composite outcome events 
(37.0 per 100 patient- years), 929 recurrent hospital-
ization (35.5 per 100 patient- years), 187 deaths (3.66 
per 100  patient- years), 687 cardiovascular events 
(20.7 per 100 patient- years), and a total of 972 “any 
event” outcomes (37.5 per 100 patient- years). Similar 
to the results from the other 2 groups, non- ABC path-
way adherent patients reported a higher rate of all 
outcomes under consideration (all P<0.001), except 
for all- cause death; mortality was numerically lower 
but did not reach statistical significance (P=0.068) 
(Figure 1C).
Kaplan–Meier curves for the composite outcome 
showed that patients managed with ABC pathway- 
adherent care had a lower cumulative risk in all 3 “clin-
ically complex” patient groups (Figure 2A through 2C).
Cox Regression Analysis
A Cox regression analysis was performed (Table 2). In 
the multimorbidity group, ABC clinical management 
was associated with a reduction in risk for the com-
posite outcome (hazard ratio [HR], 0.61, 95% CI, 0.44–
0.85, P=0.004), with a significant reduction in relative 
risk for all the other outcomes considered, in particu-
lar, for all- cause death (HR, 0.23, 95% CI, 0.06–0.94, 
P=0.041) (Table 2).
In the polypharmacy group, adjusted risk reduction 
for the composite outcome approached statistical 
significance (HR, 0.68, 95% CI, 0.47–1.00, P=0.053) 
(Table 2). A reduction in risk was found for any event 
outcome (HR, 0.68, 95% CI, 0.46–0.99, P=0.045), but 
no significant difference was found for all- cause death 
(Table 2).
Results similar to those in the multimorbidity group 
were observed for patients hospitalized at the time of 
the index event, with a significant reduction in the risk 
of the composite outcome and other secondary out-
comes, but no significant difference in the risk of all- 
cause death was found (Table 2).
Secondary Analysis
A secondary analysis was performed to compare the 
number of ABC pathway criteria fulfilled versus no ABC 
pathway criteria fulfilled (Figure 3). In the multimorbid-
ity group, there was a progressively lower risk of out-
comes according to the increasing number of ABC 
criteria fulfilled (Figure 3A), with the higher risk reduc-
tion obtained when all 3 ABC criteria are fulfilled com-
pared with no ABC criteria.
In the polypharmacy group a similar relationship be-
tween the number of ABC criteria and occurrence of out-
comes was found, albeit with a slightly lower magnitude 
than in the multimorbidity group (Figure 3B). For the oc-
currence of the all- cause death, a significant reduction in 
risk was associated with 1 ABC criterion (HR, 0.68, 95% 
CI, 0.48–0.94) or 2 ABC criteria fulfilled (HR, 0.51, 95% CI, 
0.31–0.83); however, when all 3 ABC criteria were fulfilled 
there was a nonstatistically significant reduction, with 
wide 95% CI (HR, 0.36, 95% CI, 0.12–1.18) (Figure 3B).
In the hospitalization group, a similar reduction in the 
risk of major adverse events was evident with an increas-
ing number of ABC criteria fulfilled, with the strongest 
reduction in risk for the composite outcome when all 3 
ABC criteria were fulfilled (HR, 0.45, 95% CI, 0.31–0.65). 
In all 3 “clinically complex” patients’ subgroups, increas-
ing number of ABC pathway criteria fulfilled were asso-
ciated with a progressively lower risk for the occurrence 
of “any event,” with the exception of the outcome of all- 
cause death in the polypharmacy group.
Sensitivity Analysis
We examined how much the 3 subgroups overlapped 
and what was the impact of ABC adherent man-
agement in reducing the occurrence of outcomes. 
Among the 3169 patients included in this analysis, 
only 740 (23.4%) were not included in any of the 3 
clinically complex subgroups, whereas among the 
remaining 2429 patients, 1058 (43.6%) were included 
in only 1 subgroup, 866 (35.7%) were included in 2 
subgroups, and 493 (20.8%) were included in all 3 
subgroups.
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Figure 1. Rate of major adverse events according to clinically complex subgroups.
A, Multimorbidity: composite outcome: P=0.001, hospitalization: P=0.005, all- 
cause death: P=0.005, cardiovascular events: P=0.001, any event: P=0.001; 
(B) Polypharmacy: composite outcome: P=0.014, hospitalization: P=0.021, all- 
cause death: P=0.123, cardiovascular events: P=0.041, any event: P=0.011; (C) 
Hospitalization: composite outcome: P<0.001, hospitalization: P<0.001, all- cause 
death: P=0.068, cardiovascular events: P<0.001, any event: P<0.001. ABC indicates 
Atrial fibrillation Better Care.
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Figure 2. Kaplan–Meier curves for any event according to clinically complex 
subgroups.
A, Multimorbidity; (B) Polypharmacy; (C) Hospitalization. ABC indicates Atrial 
fibrillation Better Care; dashed line, non- ABC adherent; and solid line, ABC adherent.
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The prevalence of ABC pathway adherent group 
decreased progressively from those included in only 1 
subgroup to those included in all 3 subgroups (7.4% 
versus 3.8% versus 2.4%, P<0.001). Given the low 
numbers, we considered the occurrence of only the 
primary outcome. Among those included in ≥2 sub-
groups, patients managed adherent to ABC pathway 
had a lower rate of composite outcome (57.8% versus 
non- ABC adherent, 74.0%; P=0.015). After adjust-
ment, the Cox regression analysis demonstrated that 
ABC pathway adherence among those included in ≥2 
subgroups was associated to a lower risk of the pri-
mary outcome (HR, 0.60, 95% CI, 0.44–0.96).
DISCUSSION
In this post hoc subgroup analysis derived from the 
AFFIRM trial, we showed that in clinically complex 
patient subgroups (ie, multimorbidity, polypharmacy, 
hospitalization), management with an approach con-
sistent with the one proposed by the ABC pathway, 
which streamlines the approach to AF patients’ care, 
was associated with reduction in the composite out-
come of all- cause hospitalization and all- cause death 
in all the 3 groups considered. Management consistent 
with the ABC pathway was associated with reduction 
of “any event” outcome for those clinical events con-
sidered. Further, an increasing number of ABC criteria 
fulfilled was associated with a progressively larger re-
duction in risk for most of the outcomes considered. 
Lastly, even among patients having ≥2 clinical complex 
characteristics, the adherence to ABC pathway is still 
associated with a lower risk of the composite outcome, 
reinforcing the separate evidence coming from the 3 
clinical subgroups.
The impact of the 3 clinical subgroups (ie, multimor-
bidity, polypharmacy, hospitalization) in determining an 
increased risk in major adverse events has been pre-
viously described.6–12,23 For the presence of multimor-
bidity, several observational and randomized controlled 
trials have shown an increased risk for all major adverse 
events relevant to AF patients, in particular all- cause 
death.7,8,23 Similarly, an increased risk of cardiovascu-
lar events and death is evident for AF patients report-
ing polypharmacy6,9,10 and an increased risk of death in 
hospitalized AF patients11,12 were reported. In all these 
conditions, an increased rate of events was described, 
with an increased association with risk of events that was 
found to be independent of other clinical characteristics. 
Given the increased complexity and the higher risk of 
major adverse events in those with the described clinical 
Table 2. Relationship Between Integrated Care and Major Adverse Events
ABC Adherent vs Non- ABC Adherent
Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
Multimorbidity*
Composite outcome 0.60 (0.43–0.83) 0.002 0.61 (0.44–0.85) 0.004
Hospitalization 0.61 (0.44–0.85) 0.004 0.62 (0.45–0.87) 0.006
All- cause death 0.22 (0.06–0.88) 0.033 0.23 (0.06–0.94) 0.041
Cardiovascular events 0.53 (0.34–0.83) 0.005 0.54 (0.35–0.84) 0.007
Any event 0.59 (0.42–0.82) 0.002 0.60 (0.43–0.84) 0.003
Polypharmacy†
Composite outcome 0.67 (0.46–0.98) 0.038 0.68 (0.47–1.00) 0.053
Hospitalization 0.68 (0.45–0.99) 0.042 0.69 (0.46–1.01) 0.058
All- cause death 0.50 (0.16–1.56) 0.23 0.49 (0.16–1.54) 0.22
Cardiovascular events 0.66 (0.41–1.06) 0.087 0.67 (0.41–1.08) 0.099
Any event 0.66 (0.45–0.97) 0.033 0.68 (0.46–0.99) 0.045
Hospitalization‡
Composite outcome 0.59 (0.41–0.83) 0.003 0.59 (0.42–0.85) 0.004
Hospitalization 0.57 (0.40–0.82) 0.003 0.58 (0.40–0.84) 0.004
All- cause death 0.51 (0.19–1.36) 0.18 0.49 (0.18–1.33) 0.16
Cardiovascular events 0.48 (0.30–0.76) 0.002 0.48 (0.30–0.77) 0.002
Any event 0.58 (0.41–0.83) 0.002 0.59 (0.41–0.84) 0.003
ABC indicates Atrial fibrillation Better Care; AF, atrial fibrillation; and HR, hazard ratio.
*Multivariate analysis adjusted for age, sex, first AF episode, use of aspirin.
†Multivariate analysis adjusted for age, sex, first AF episode, diabetes mellitus, hepatic/renal disease, pulmonary disease.
‡Multivariate analysis adjusted for age, sex, first AF episode, diabetes mellitus, hepatic/renal disease, pulmonary disease, use of aspirin.D
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Figure  3. Relationship between number of ABC criteria and major 
adverse events according to clinically complex subgroups.
A, Multimorbidity group analysis adjusted for age, sex, first AF episode, 
use of aspirin; (B) Polypharmacy group analysis adjusted for age, sex, first 
AF episode, diabetes mellitus, hepatic/renal disease, pulmonary disease; 
(C) Hospitalization group analysis adjusted for age, sex, first AF episode, 
diabetes mellitus, hepatic/renal disease, pulmonary disease, use of aspirin. 
ABC indicates Atrial fibrillation Better Care; and HR, hazard ratio.
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features, an approach consistent with the ABC pathway 
may be beneficial. Indeed, a large group of patients were 
included in at least 2 of the subgroups and hence, had 
even greater clinical complexity.
Streamlining decision making to facilitate man-
agement of clinically complex patients with AF start-
ing with primary care and linking with secondary 
care (including cardiologist and noncardiologists) 
may improve outcomes. The ABC pathway has been 
proposed as a simple and pragmatic approach to 
streamline and integrate care.16 Thus far, the ABC 
pathway has been tested indirectly, but it appears to 
reduce major adverse events in patients with AF.17–19 
Prior studies have assessed several clinical settings 
and patients’ characteristics including the overall 
AFFIRM cohort.17–19
In our study, together with the previous analysis on 
the ABC pathway in AFFIRM,17 we found a low per-
centage of patients treated as fully adherent to the 
ABC pathway compared with other studies.18,19 In a 
prospective Italian observational cohort, for example, 
management adherent with the ABC pathway was 
associated with a 56% risk reduction for a compos-
ite outcome of cardiovascular events.18 Similarly, in a 
population- based nationwide cohort, there was a sig-
nificant reduction (≈15%) in all adverse outcomes with 
ABC pathway- adherent management.19 Considering 
the time of the AFFIRM study enrollment (>15 years 
ago), it is possible that a clinical management based 
on a single- disease approach was more common in 
the past, compared with current practice, in which 
holistic and integrated management is more used.
In the present post hoc analysis, even in high- 
risk subgroups, where the risk of adverse events is 
high, use of an ABC pathway approach was asso-
ciated with fewer AF- related outcomes. The adju-
dicated outcomes of hospitalization and all- cause 
death were reduced in all 3 subgroups. The risk for 
hospitalization (considered as a single outcome) was 
also reduced with similar magnitude. Nonetheless, 
we may be underpowered to assess reduction in all- 
cause death in the polypharmacy and hospitaliza-
tion groups.
Our secondary analysis showed that risk was pro-
gressively lowered with a progressively higher numbers 
of ABC criteria fulfilled. This trend was also evident for 
all- cause death in the polypharmacy and hospitaliza-
tion groups. The low number of events in the fully ABC 
pathway- adherent group is a limitation; however, the 
consistency of results in the patients with even higher 
clinical complexity reinforces the idea that the more 
complex patient is much more likely to get a beneficial 
effect from a comprehensive and integrated approach 
to AF care. Indeed, utilization of the ABC pathway 
was associated with reduction in “any clinical event” 
among these clinically complex patients, which further 
emphasizes the importance of improving the overall 
management of AF patients comprehensively, beyond 
thromboembolic risk.24
Limitations
The post hoc nature, the modest number of subjects 
in the ABC compliant groups compared with the over-
all cohort (which limits the reliability of Kaplan–Meier 
analysis) and the relatively aged data set are limitations 
to this analysis. Because the AFFIRM study is an old 
clinical trial, this could limit the generalizability of our re-
sults, given the changes in AF management practices 
that have occurred in the past 15  years. Also, other 
general management aspects of AF patients (such as 
weight management, evaluation/management of sleep 
apnea, etc) were not routinely assessed at the time of 
the AFFIRM study and were not reported in the trial data 
set. The AFFIRM trial compared rhythm versus rate con-
trol, but this was not the objective of the present study, 
which focused on “better symptom” management over-
all (even within the heart failure subgroup, where rhythm 
control with catheter ablation has been beneficial com-
pared with only drug therapy25). Nonetheless, we be-
lieve that the AFFIRM study design, which included 
patients with significant risk factors, still gives a good 
representation of the “typical” AF population.
Conversely, the adjudicated outcomes and the 
largely proved reliability of the AFFIRM database makes 
this hypothesis generating analysis reliable. Indeed, 
these results, supported by previous evidence, en-
courages use of an ABC pathway- adherent approach, 
to streamline and integrate care in clinically complex 
patients with AF.
CONCLUSIONS
Management of AF by an ABC consistent pathway 
is associated with reduction in major adverse events 
in clinically complex AF patients, including those with 
multimorbidity, polypharmacy, and prior hospitaliza-
tion. These exploratory findings need further confirma-
tion in larger, more contemporary studies.
ARTICLE INFORMATION
Received October 11, 2019; accepted March 13, 2020.
Affiliations
From the Liverpool Centre for Cardiovascular Science, University of Liverpool 
and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom (M.P., 
D.A.L., G.Y.H.L.); Department of Clinical Sciences and Community Health, 
University of Milan, Italy (M.P.); Geriatric Unit, Fondazione IRCCS Ca’ Granda, 
Ospedale Maggiore Policlinico, Milan, Italy (M.P.); Department of Internal 
Medicine and Medical Specialties, Sapienza-University of Rome, Italy (G.F.R.); 
Division of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, 
Iowa City, IA (B.O.); Aalborg Thrombosis Research Unit, Department of Clinical 
Medicine, Aalborg University, Aalborg, Denmark (D.A.L., G.Y.H.L.).
D
ow
nloaded from
 http://ahajournals.org by on July 6, 2020
J Am Heart Assoc. 2020;9:e014932. DOI: 10.1161/JAHA.119.014932 10
Proietti et al ABC in Clinically Complex AF Patients
Sources of Funding
None.
Disclosures
Proietti reports consulting activity for Boehringer Ingelheim; Olshansky has 
been consultant for Lundbeck, Amarin, Boehringer Ingelheim; Lane reports 
educational grants from Bristol- Myers Squibb and Boehringer Ingelheim, 
speaker activity for Pfizer, and consultant activity for Bristol- Myers Squibb, 
Bayer and Boehringer Ingelheim; Lip has served as consultant for Bayer/
Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife, 
and Daiichi- Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer 
Ingelheim, Microlife, Roche, and Daiichi- Sankyo. No fees are received per-
sonally. The remaining authors have no disclosures to report.
REFERENCES
 1. Proietti M, Laroche C, Nieuwlaat R, Crijns HJGM, Maggioni AP, Lane 
DA, Boriani G, Lip GYH. Increased burden of comorbidities and risk 
of cardiovascular death in atrial fibrillation patients in Europe over ten 
years: a comparison between EORP- AF pilot and EHS- AF registries. 
Eur J Intern Med. 2018;55:28–34.
 2. Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GYH; 
AF Gen Pilot Investigators. “Real- world” atrial fibrillation management in 
Europe: observations from the 2- year follow- up of the EURObservational 
Research Programme- Atrial Fibrillation General Registry Pilot Phase. 
Europace. 2017;19:722–733.
 3. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant 
D, Ivanes F, Babuty D, Lip GYH. Causes of death and influenc-
ing factors in patients with atrial fibrillation. Am J Med. 2016;129: 
1278–1287.
 4. Marijon E, Le Heuzey J-Y, Connolly S, Yang S, Pogue J, Brueckmann 
M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, et al. Causes 
of death and influencing factors in patients with atrial fibrillation: a 
competing- risk analysis from the randomized evaluation of long- term 
anticoagulant therapy study. Circulation. 2013;128:2192–2201.
 5. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, Calvo-
Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Causes of death 
in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 
2016;68:2508–2521.
 6. Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major 
adverse events in atrial fibrillation: observations from the AFFIRM trial. 
Clin Res Cardiol. 2016;105:412–420.
 7. Proietti M, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, Basili 
S, Mannucci PM, Boriani G, Lip GYH, et al. Long- term relationship be-
tween atrial fibrillation, multimorbidity and oral anticoagulant drug use. 
Mayo Clin Proc. 2019;94:2427–2436.
 8. Jani BD, Nicholl BI, McQueenie R, Connelly DT, Hanlon P, Gallacher 
KI, Lee D, Mair FS. Multimorbidity and co- morbidity in atrial fibrillation 
and effects on survival: findings from UK Biobank cohort. Europace. 
2018;20:f329–f336.
 9. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, 
Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, et al. 
Polypharmacy and the efficacy and safety of rivaroxaban versus warfa-
rin in the prevention of stroke in patients with nonvalvular atrial fibrilla-
tion. Circulation. 2016;133:352–360.
 10. Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes 
RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, et  al. 
Polypharmacy and effects of apixaban versus warfarin in patients 
with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 
2016;353:i2868.
 11. Piazza G, Hurwitz S, Harrigan L, Jenkins K, Hohlfelder B, Fanikos J, 
Goldhaber S. Anticoagulation and mortality rates among hospitalized 
patients with atrial fibrillation. TH Open. 2018;02:e33–e38.
 12. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, 
Mahaffey KW, Gersh BJ, Hylek E, Naccarelli G, et al. Drivers of hospi-
talization for patients with atrial fibrillation: results from the Outcomes 
Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT- AF). 
Am Heart J. 2014;167:735–742.e2.
 13. Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan 
R, Lau DH, Sanders P, Hendriks JML. Integrated care in atrial fibrillation: 
a systematic review and meta- analysis. Heart. 2017;103:1947–1953.
 14. Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, 
Arnar D, Atar D, Auricchio A, Bax J, et al. Integrating new approaches 
to atrial fibrillation management: the 6th AFNET/EHRA Consensus 
Conference. Europace. 2018;20:395–407.
 15. Kirchhof P. The future of atrial fibrillation management: integrated care 
and stratified therapy. Lancet. 2017;390:1873–1887.
 16. Lip GYH. The ABC pathway: an integrated approach to improve AF 
management. Nat Rev Cardiol. 2017;14:627–628.
 17. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved out-
comes by integrated care of anticoagulated patients with atrial fibrilla-
tion using the simple ABC (Atrial Fibrillation Better Care) pathway. Am J 
Med. 2018;131:1359–1366.e6.
 18. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated care 
management of patients with atrial fibrillation and risk of cardiovascular 
events. Mayo Clin Proc. 2019;94:1261–1267.
 19. Yoon M, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S, Kim J-Y, Sung J-H, 
Pak H-N, Lee M-H, et al. Improved population- based clinical outcomes 
of patients with atrial fibrillation by compliance with the simple ABC 
(Atrial Fibrillation Better Care) pathway for integrated care management: 
a nationwide cohort study. Thromb Haemost. 2019;19:1695–1703.
 20. Greene HL. Atrial fibrillation follow- up investigation of rhythm manage-
ment—the AFFIRM study design. Am J Cardiol. 1997;79:1198–1202.
 21. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron 
EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, et al. A comparison 
of rate control and rhythm control in patients with atrial fibrillation. N 
Engl J Med. 2002;347:1825–1833.
 22. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. 
Multimorbidity in general practice: prevalence, incidence, and determi-
nants of co- occurring chronic and recurrent diseases. J Clin Epidemiol. 
1998;51:367–375.
 23. Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, 
Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, et  al. 
Outcomes of apixaban versus warfarin in patients with atrial fibrillation 
and multi- morbidity: insights from the ARISTOTLE trial. Am Heart J. 
2019;208:123–131.
 24. Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk 
assessment in patients with atrial fibrillation: a balance of evidence, 
practicality and precision. Thromb Haemost. 2018;118:2014–2017.
 25. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma 
L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, et  al. 
Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 
2018;378:417–427.
D
ow
nloaded from
 http://ahajournals.org by on July 6, 2020
